RxDoctor Payments Data

Aijaz Nanjiani

Psychiatry · Paramus, NJNPI 1639266943

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $89,674 of the $95,019 with a category attached, or 94.4%. AbbVie accounts for 91.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $20,915 and has fallen 57.8% since, to $8,824 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,019in general payments, 2019–2025

Across 283 payments — averaging $335.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$87K
  • Otsuka America Pharmaceutical, Inc.$7K
  • Sunovion Pharmaceuticals Inc.$253
  • Lundbeck LLC$151
  • Johnson & Johnson$28
  • Vanda Pharmaceuticals Inc.$27
  • plus $44 from 3 others

What the payments were for

  • Speaking & faculty fees$89,67494%
  • Travel & lodging$230%
  • Food & beverage$5,3226%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)219$87,172
Otsuka America Pharmaceutical, Inc.14$7,344
Sunovion Pharmaceuticals Inc.26$253
Lundbeck LLC17$151
Johnson & Johnson2$28
Vanda Pharmaceuticals Inc.2$27
Bausch Health US, LLC1$18
Alkermes, Inc.1$15
Validus Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,019 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl231$340,367
FanaptIloperidone158$328,747
IngrezzaValbenazine Tosylate12$97,179
Chlorpromazine Hcl249$88,699
Divalproex Sodium ErDivalproex Sodium1,276$87,542
Invega SustennaPaliperidone Palmitate24$70,302
Divalproex Sodium1,110$66,001
NuplazidPimavanserin Tartrate12$58,973
AristadaAripiprazole Lauroxil16$52,549
Risperidone2,661$49,247
Aripiprazole932$48,169
Quetiapine Fumarate1,426$44,728
RexultiBrexpiprazole32$44,671
NuedextaDextromethorphan Hbr/Quinidine28$43,889
Fluvoxamine Maleate688$33,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Namzaric$87,172$348,042243 claims
Vanda Pharmaceuticals Inc.Fanapt$27$328,747158 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$7,344$74,69944 claims
Johnson & JohnsonInvega Sustenna$28$70,30224 claims
Alkermes, Inc.Aristada$15$52,54916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →